raltegravir

Type: Keyphrase
Name: raltegravir
First reported Sep 30 2014 - Updated Sep 30 2014 - 1 reports

FDA approves two new doses of elvitegravir, in addition to its current use in Stribild

Facebook Twitter Google + Email PrintOn September 24, 2014, the FDA approved two new standalone doses of the integrase inhibitor elvitegravir, which now comes with the brand name Vitekta. The 85mg dose can be taken with Reyataz (atazanavir) and Kaletra ... [Published Project Inform - Sep 30 2014]
First reported Sep 29 2014 - Updated Sep 30 2014 - 1 reports

New FDA HIV Drug Approvals Unlikely to Have Much Impact, Unless ...

If you're an ID doc based in the U.S., you probably received notice last week that two new HIV drugs were approved -- cobicistat and elvitegravir .And if you're wondering what the big deal is, welcome to the club. In fact, the Canadians beat us to the ... [Published The Body - Sep 29 2014]
First reported Sep 25 2014 - Updated Sep 26 2014 - 3 reports

Elvitegravir / Vitekta FDA Approval

On September 24, 2014, FDA approved Vitekta (elvitegravir) 85 mg and 150 mg tablets. Vitekta is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor indicated in combination with an HIV protease inhibitor coadministered with ... [Published National AIDS Treatment Advocacy Project - Sep 26 2014]
First reported Sep 19 2014 - Updated Sep 19 2014 - 1 reports

Could an Integrase Inhibitor Have Prevented One More HIV Infection?

By .From TheBodyPRO.comSeptember 19, 2014Monica Gomes, M.D., M.Sc., is an infectious diseases and neurologist specialist who works at Hospital de Clínicas in Curitiba, Brazil. She is also assistant professor of the internal medicine department at the ... [Published The Body - Sep 19 2014]
First reported Sep 11 2014 - Updated Sep 11 2014 - 1 reports

Bone Mineral Density Over 96 Weeks in Adults Failing First-Line Therapy Randomized to Raltegravir/Lopinavir/Ritonavir Compared With Standard Second-Line Therapy

Objective: To compare bone mineral density (BMD) changes over 96 weeks in adults virologically failing standard first-line therapy, randomized to raltegravir plus lopinavir/ritonavir (RAL + LPV/r) or conventional 2-3 nucleoside/nucleotide reverse transcriptase ... [Published JAIDS - Sep 11 2014]
First reported Sep 09 2014 - Updated Sep 09 2014 - 1 reports

Efficacy and Safety of Raltegravir in Racial Groups

ICAAC 2014 54th Interscience Conferenceon Antimicrobial Agents and ChemotherapySeptember 5-9, 2014, Washington, DC Reported by Jules LevinICAAC 2014. September 5-9, 2014. Washington, DCKathleen Squires1, Linda-Gale Bekker2, Christine Katlama3, Yazdan ... [Published National AIDS Treatment Advocacy Project - Sep 09 2014]
First reported Sep 05 2014 - Updated Sep 05 2014 - 1 reports

[Department of Error] Department of Error

Raffi F, Rachlis A, Stellbrink H-J, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 2013; 381: 735–43—The ... [Published The Lancet - Sep 05 2014]
First reported Sep 05 2014 - Updated Sep 05 2014 - 1 reports

Data on HIV/AIDS Discussed by Researchers at GlaxoSmithKline (Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or...

Data on HIV/AIDS Discussed by Researchers at GlaxoSmithKline (Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study)By a News Reporter-Staff News Editor ... [Published 4 Traders - Sep 05 2014]
First reported Aug 25 2014 - Updated Aug 25 2014 - 1 reports

Raltegravir in Virologically Suppressed Overweight Women

Baker JV, Neuhaus J, Duprez D et al . Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. J Acquir Immune Defic Syndr 2011; 56: 36–43.Brown TT, ... [Published General Medicine eJournal - Aug 25 2014]
First reported Aug 11 2014 - Updated Aug 11 2014 - 1 reports

Human medicines European public assessment report (EPAR): Isentress, raltegravir, Revision: 22, Authorised

First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

Charcot Project: INSPIRE Trial fully recruited

The INSPIRE Study is now fully recruited. #MSBlog #MSResearch "In response to several requests, I can now confirm that recruitment for the INSPIRE Study is now complete. The study will be closed when the last subject completes 6 months, i.e. early ... [Published Multiple Sclerosis Research - Jul 30 2014]
First reported Jun 05 2014 - Updated Jun 06 2014 - 4 reports

Merck begins patient enrollment in Phase III trial of HIV-drug Isentress

Merck has started patient enrollment in its global Phase III clinical trial 'ONCEMRK', which is evaluating a once-daily investigational formulation of Isentress (raltegravir), known as reformulated raltegravir, as part of combination HIV therapy for treatment-naïve ... [Published PBR - News - Jun 06 2014]

Quotes

"......The key findings of this study are the following: (i) autologous HSCT using apheresis products collected prior to infection is feasible in SHIV-infected RMs; (ii) as expected, the myeloablative TBI used for conditioning induced a massive reset of the lympho-hematopoietic compartment, consequently resulting in the depletion of 94.2-99.2% of circulating CD4+ T-cells; (iii) animals receiving autologous HSCT under ART exhibited a prompt and pronounced decline in the peripheral blood viral reservoir (with undetectable SHIV-DNA in PBMCs in two out of three RMs) and maintained undetectable SHIV-RNA viremia with the exception of a few minor blips; (iv) two of the three transplanted RMs showed a very rapid rebound of viremia after ART interruption; and (v) the third transplanted RM, who was sacrificed for clinical reasons at day fourteen post ART interruption, had no detectable virus in plasma, PBMCs, tonsils, and GI tract, low but detectable levels of SHIV-DNA in sorted peripheral CD4+ T-cells and lymph nodes, and moderate levels of SHIV-DNA in the spleen....."
"An SVR12 rate of 93.5% was achieved with 12 weeks of 3D plus ribavirin, with only two patients not meeting that benchmark, and an SVR4 rate of 96.9% was achieved with 24 weeks of 3D + RBV, with only one patient not meeting that benchmark" said Joe Eron, M D , of the University of North Carolina Medical School, who presented the study findings
"Virologic outcomes were similar across the treatment arms through 96 weeks" the agency stated in a news release
This marked the second trip through the FDA approval process for both drugs; they were rejected in April 2013 on the basis of "deficiencies in documentation and validation of certain quality testing procedures and methods" according to Gilead Sciences, which markets the two medications

More Content

All (42) | News (29) | Reports (0) | Blogs (13) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Einstein & Montefiore Investigators Present Res... [Published Newswise - 11 hours ago]
FDA approves two new doses of elvitegravir, in ... [Published Project Inform - Sep 30 2014]
New FDA HIV Drug Approvals Unlikely to Have Muc... [Published The Body - Sep 29 2014]
Elvitegravir / Vitekta FDA Approval [Published National AIDS Treatment Advocacy Project - Sep 26 2014]
Persistence of Virus Reservoirs in ART-Treated ... [Published National AIDS Treatment Advocacy Project - Sep 26 2014]
For HIV/HCV Coinfected Patients, 3D With Ribavi... [Published The Body - Sep 26 2014]
Gilead receives approval for two HIV-1 cocktail... [Published Drugtopics.com - Sep 26 2014]
FDA Approves 2 HIV-1 Cocktail Drugs [Published Diabetes Care - Sep 25 2014]
Tybost (Cobicistat) and Vitekta (Elvitegravir) ... [Published The Body - Sep 25 2014]
Could an Integrase Inhibitor Have Prevented One... [Published The Body - Sep 19 2014]
HIV and the SANDF: Interview with Dr Heila Redpath [Published News24 - Sep 19 2014]
Use of Third Line Antiretroviral Therapy in Lat... [Published Plosone.org - Sep 15 2014]
ECTRIMS 2014: HERVs are officially a therapeuti... [Published Multiple Sclerosis Research - Sep 15 2014]
Cipla enters into a licensing agreement with Gi... [Published India Infoline - Sep 15 2014]
Health Insurance Companies Are the Biggest Impe... [Published The Body - Sep 12 2014]
Bone Mineral Density Over 96 Weeks in Adults Fa... [Published JAIDS - Sep 11 2014]
Improved Single Copy Assays for Quantification ... [Published National AIDS Treatment Advocacy Project - Sep 10 2014]
Efficacy and Safety of Raltegravir in Racial Gr... [Published National AIDS Treatment Advocacy Project - Sep 09 2014]
ICAAC 2014: AbbVie 3D Regimen Works Well for Pe... [Published HIV and Hepatitis.com - Sep 08 2014]
[Department of Error] Department of Error [Published The Lancet - Sep 05 2014]
Data on HIV/AIDS Discussed by Researchers at Gl... [Published 4 Traders - Sep 05 2014]
Advances in the works for STDs [Published Examiner.com - Aug 29 2014]
The Role of Triumeq in HIV Treatment [Published The Body - Aug 26 2014]
Raltegravir in Virologically Suppressed Overwei... [Published General Medicine eJournal - Aug 25 2014]
Cipla consolidated net dips by 39% in Q1 [Published PharmaBiz - Aug 16 2014]
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Aug 11 2014]
[Articles] Ritonavir-boosted darunavir combined... [Published The Lancet online - Aug 05 2014]
Charcot Project: INSPIRE Trial fully recruited [Published Multiple Sclerosis Research - Jul 30 2014]
Opinion/decision on a Paediatric Investigation ... [Published Opinion/decision on a Paediatric Investigation ... - Jul 15 2014]
Merck begins patient enrollment in Phase III tr... [Published PBR - News - Jun 06 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
ECTRIMS 2014: HERVs are officially a therapeuti... [Published Multiple Sclerosis Research - Sep 15 2014]
Can we reduce human endogenous retroviruses or HERVs with a treatment? #MSBlog #MSResearch "Just arrived back from Boston; exhausted physically, mentally and no doubt more to come with jet-lag. One of the highlights for me at ECTRIMS was the interest ...
[Department of Error] Department of Error [Published The Lancet - Sep 05 2014]
Raffi F, Rachlis A, Stellbrink H-J, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 2013; 381: 735–43—The ...
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Aug 11 2014]
[Articles] Ritonavir-boosted darunavir combined... [Published The Lancet online - Aug 05 2014]
Our NtRTI-sparing regimen was non-inferior to standard treatment and represents a treatment option for patients with CD4 cell counts higher than 200 cells per μL. ...
Charcot Project: INSPIRE Trial fully recruited [Published Multiple Sclerosis Research - Jul 30 2014]
The INSPIRE Study is now fully recruited. #MSBlog #MSResearch "In response to several requests, I can now confirm that recruitment for the INSPIRE Study is now complete. The study will be closed when the last subject completes 6 months, i.e. early ...
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.